Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

被引：119

作者：

Lyke, Kirsten E. ^{[1
]}

Atmar, Robert L. ^{[2
]}

Islas, Clara Dominguez ^{[3
]}

Posavad, Christine M. ^{[3
,4
]}

Szydlo, Daniel ^{[5
]}

Chourdhury, Rahul Paul ^{[5
]}

Deming, Meagan E. ^{[1
]}

Eaton, Amanda ^{[6
]}

Jackson, Lisa A. ^{[7
]}

Branche, Angela R. ^{[8
]}

Sahly, Hana M. El ^{[2
]}

Rostad, Christina A. ^{[9
]}

Martin, Judith M. ^{[10
]}

Johnston, Christine ^{[3
,4
,11
]}

Rupp, Richard E. ^{[12
]}

Mulligan, Mark J. ^{[13
]}

Brady, Rebecca C. ^{[14
]}

Frenck, Robert W., Jr. ^{[14
]}

Backer, Martin ^{[15
]}

Kottkamp, Angelica C. ^{[13
]}

Babu, Tara M. ^{[11
]}

Rajakumar, Kumaravel ^{[10
]}

Edupuganti, Srilatha ^{[16
,17
]}

Dobrzynski, David ^{[8
]}

Coler, Rhea N. ^{[18
,19
]}

Archer, Janet I. ^{[20
]}

Crandon, Sonja ^{[21
]}

Zemanek, Jillian A. ^{[5
]}

Brown, Elizabeth R. ^{[3
]}

Neuzil, Kathleen M. ^{[1
]}

Stephens, David S. ^{[16
]}

Post, Diane J. ^{[21
]}

Nayak, Seema U. ^{[21
]}

Suthar, Mehul S. ^{[22
]}

Roberts, Paul C. ^{[21
]}

Beigel, John H. ^{[21
]}

Montefiori, David C. ^{[23
]}

DMID Std Grp

机构：

[1] Univ Maryland Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA

[2] Baylor Coll Med, Dept Med & Mol Virol & Microbiol, Houston, TX 77030 USA

[3] Univ Washington, Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA USA

[4] Univ Washington, Fred Hutchinson Canc Res Ctr, Dept Lab Med & Pathol, Seattle, WA USA

[5] Univ Washington, Stat Ctr HIV AIDS Res & Prevent SCHARP, Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[6] Duke Univ Med Ctr, Dept Surg, Durham, NC USA

[7] Kaiser Permanente Washington Hlth Res Inst, Seattle, WA USA

[8] Univ Rochester, Dept Med, Div Infect Dis, Rochester, NY USA

[9] Emory Univ Sch Med & Childrens Healthcare Atlanta, Ctr Childhood Infect & Vaccines, Dept Pediat, Atlanta, GA USA

[10] Univ Pittsburgh Sch Med, Dept Pediat, Pittsburgh, PA USA

[11] Univ Washington, Dept Med, Seattle, WA USA

[12] Univ Texas Med Branch, Sealy Inst Vaccine Sci, Galveston, TX USA

[13] NYU Langone Vaccine Ctr, NYU Grossman Sch Med, Dept Med, Div Infect Dis & Immunol, New York, NY USA

[14] Univ Cincinnati Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, Cincinnati, OH USA

[15] NYU Langone Hosp, Mineola, NY USA

[16] Emory Univ Sch Med, Dept Med, Atlanta, GA USA

[17] Hope Clin Emory Vaccine Ctr, Atlanta, GA USA

[18] Univ Washington Sch Med, Seattle Childrens Res Inst, Seattle, WA USA

[19] Univ Washington Sch Med, Dept Pediat, Seattle, WA USA

[20] FHI360, Durham, NC 27701 USA

[21] Natl Inst Allergy & Infect Dis, NIH, Div Microbiol & Infect Dis, Bethesda, MD USA

[22] Emory Univ, Atlanta, GA USA

[23] Duke Univ Med Ctr, Duke Human Vaccine Inst, Durham, NC 27710 USA

来源：

CELL REPORTS MEDICINE | 2022年 / 3卷 / 07期

基金：

美国国家卫生研究院;

关键词：

BA.2.12.1; BA.4/BA.5; booster; COVID-19; mRNA vaccine; neutralizing antibody; Omicron variant; recombinant adenovirus vaccine; SARS-CoV-2; sublineage;

D O I：

10.1016/j.xcrm.2022.100679

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost to generate protective immunity. We assess the magnitude and short-term durability of neutralizing antibodies after homologous and heterologous boosting with mRNA and Ad26.COV2.S vaccines. All prime-boost combinations substantially increase the neutralization titers to Omicron, although the boosted titers decline rapidly within 2 months from the peak response compared with boosted titers against the prototypic D614G variant. Boosted Omicron neutralization titers are substantially higher for homologous mRNA vaccine boosting, and for heterologous mRNA and Ad26.COV2.S vaccine boosting, compared with homologous Ad26.COV2.S boosting. Homologous mRNA vaccine boosting generates nearly equivalent neutralizing activity against Omicron sublineages BA.1, BA.2, and BA.3 but modestly reduced neutralizing activity against BA.2.12.1 and BA.4/BA.5 compared with BA.1. These results have implications for boosting requirements to protect against Omicron and future variants of SARS-CoV-2.

引用

页数：13

共 50 条

[21] Neutralizing and enhancing antibodies against SARS-CoV-2
Liu, Yafei
Arase, Hisashi
INFLAMMATION AND REGENERATION, 2022, 42 (01)
[22] Neutralizing and enhancing antibodies against SARS-CoV-2
Yafei Liu
Hisashi Arase
Inflammation and Regeneration, 42
[23] A polyvalent RNA vaccine reduces the immune imprinting phenotype in mice and induces neutralizing antibodies against omicron SARS-CoV-2
Rocha, Vinicius Pinto Costa
Machado, Bruna Aparecida Souza
Barreto, Breno Cardim
Quadros, Helenita Costa
Fernandes, Antonio Marcio Santana
Lima, Eduarda dos Santos
Bandeira, Mariana Evangelista
Meira, Cassio Santana
Fonseca, Larissa Moraes dos Santos
Erasmus, Jesse
Khandhar, Amit
Berglund, Peter
Reed, Steve
Badaro, Roberto Jose da Silva
Soares, Milena Botelho Pereira
HELIYON, 2024, 10 (04)
[24] Neutralizing SARS-CoV-2 Spike Antibodies against Omicron in Paired Samples after Two or Three Doses of mRNA Vaccine
Debes, Amanda K.
Xiao, Shaoming
Egbert, Emily R.
Caturegli, Patrizio
Gadala, Avinash
Colantuoni, Elizabeth
Sitaras, Ioannis
Pekosz, Andrew
Milstone, Aaron M.
MICROBIOLOGY SPECTRUM, 2022, 10 (05):
[25] A Unique mRNA Vaccine Elicits Protective Efficacy against the SARS-CoV-2 Omicron Variant and SARS-CoV
Guan, Xiaoqing
Verma, Abhishek K.
Wang, Gang
Roy, Abhijeet
Perlman, Stanley
Du, Lanying
VACCINES, 2024, 12 (06)
[26] Comparative Analysis of Vaccine-Induced Neutralizing Antibodies against the Alpha, Beta, Delta, and Omicron Variants of SARS-CoV-2
Girl, Philipp
von Buttlar, Heiner
Mantel, Enrico
Antwerpen, Markus H.
Woelfel, Roman
Mueller, Katharina
VACCINES, 2024, 12 (05)
[27] An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
Li, Tao
Luo, Deyan
Ning, Nianzhi
Wang, Xin
Zhang, Liangyan
Yang, Xiaolan
Li, Deyu
Sun, Yakun
Yu, Wenjing
Wei, Wenjin
Wang, Hui
EMERGING MICROBES & INFECTIONS, 2023, 12 (01)
[28] Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination
Dapporto, Francesca
Marchi, Serena
Leonardi, Margherita
Piu, Pietro
Lovreglio, Piero
Decaro, Nicola
Buonvino, Nicola
Stufano, Angela
Lorusso, Eleonora
Bombardieri, Emilio
Ruello, Antonella
Viviani, Simonetta
Molesti, Eleonora
Trombetta, Claudia Maria
Manenti, Alessandro
Montomoli, Emanuele
JOURNAL OF IMMUNOLOGY RESEARCH, 2022, 2022
[29] Bioinformatics approach for the construction of multiple epitope vaccine against omicron variant of SARS-CoV-2
Sumera Zaib
Fatima Akram
Syed Talha Liaqat
Muhammad Zain Altaf
Imtiaz Khan
Ayed A. Dera
Jalal Uddin
Ajmal Khan
Ahmed Al-Harrasi
Scientific Reports, 12
[30] Rapid isolation of pan-neutralizing antibodies against Omicron variants from convalescent individuals infected with SARS-CoV-2
Yu, Peng
Ran, Jingping
Yang, Ruiqi
Zhu, Hang
Lu, Song
Wu, Yuzhang
Zhao, Tingting
Xiong, Tianchen
FRONTIERS IN IMMUNOLOGY, 2024, 15

← 1 2 3 4 5 →